Product Description
Mechanisms of Action: DRI Inhibitor,NRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sumitomo Pharma America, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Binge-Eating Disorder|Bulimia Nervosa|Attention Deficit Disorder with Hyperactivity
Phase 2: Attention Deficit Disorder with Hyperactivity|Depressive Disorder, Major
Phase 1: Attention Deficit Disorder with Hyperactivity|Bulimia Nervosa|Binge-Eating Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SEP360-322 | P3 |
Completed |
Binge-Eating Disorder|Bulimia Nervosa |
2019-06-24 |
|
| SEP-360-311 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2019-03-15 |
|
| SEP360-321 | P3 |
Completed |
Bulimia Nervosa|Binge-Eating Disorder |
2018-05-16 |
|
| SEP360-305 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2017-02-28 |